📣 VC round data is live. Check it out!

Centene Valuation Multiples

Discover revenue and EBITDA valuation multiples for Centene and similar public comparables like New China Life Insurance, Helvetia Baloise Holding, Aviva, Cincinnati Financial and more.

Centene Overview

About Centene

Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.


Founded

1993

HQ

United States

Employees

61.1K

Financials (LTM)

Revenue: $193B
EBITDA: $2B

EV

$19B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Centene Financials

Centene reported last 12-month revenue of $193B and EBITDA of $2B.

In the same LTM period, Centene generated $191B in gross profit, $2B in EBITDA, and $1B in net income.

Revenue (LTM)


Centene P&L

In the most recent fiscal year, Centene reported revenue of $195B and EBITDA of $1B.

Centene is profitable as of last fiscal year, with gross margin of 7%, EBITDA margin of 1%, and net margin of 1%.

See analyst estimates for Centene
LTMLast FY202320242025202620272028
Revenue$193B$195B$154B$163B$195B
Gross Profit$191B$14B$17B$17B$14B
Gross Margin99%7%11%10%7%
EBITDA$2B$1B$6B$6B($5B)
EBITDA Margin1%1%4%4%(2%)
EBIT Margin0%0%2%2%(0%)
Net Profit$1B$1B$3B$3B($7B)
Net Margin1%1%2%2%(3%)

Financial data powered by Morningstar, Inc.

Centene Stock Performance

Centene has current market cap of $26B, and enterprise value of $19B.

Market Cap Evolution


Centene's stock price is $52.98.

Centene share price decreased by 1.3% in the last 30 days, and by 6.1% in the last year.

Centene has an EPS (earnings per share) of $2.08.

See more trading valuation data for Centene
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$19B$26B0.0%-1.3%18.0%-6.1%$2.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Centene Valuation Multiples

Centene trades at 0.1x EV/Revenue multiple, and 12.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Centene

EV / Revenue (LTM)


Centene Financial Valuation Multiples

As of May 8, 2026, Centene has market cap of $26B and EV of $19B.

Centene has a P/E ratio of 20.7x.

LTMLast FY202320242025202620272028
EV/Revenue0.1x0.1x0.1x0.1x0.1x
EV/EBITDA12.3x14.6x3.3x3.0x(3.9x)
EV/EBIT21.2x49.7x5.4x5.9x(60.2x)
EV/Gross Profit0.1x1.4x1.1x1.1x1.4x
P/E20.7x25.4x9.7x7.9x(3.9x)
EV/FCF4.1x4.0x2.6x(38.3x)4.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Centene Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Centene Margins & Growth Rates

Centene decreased revenue by 2% but EBITDA grew by 56% in the last fiscal year.

In the most recent fiscal year, Centene reported gross margin of 7%, EBITDA margin of 1%, and net margin of 1%.

See estimated margins and future growth rates for Centene

Centene Margins

Last FY202420252026202720282029
Gross Margin7%10%7%99%
EBITDA Margin1%4%(2%)1%
EBIT Margin0%2%(0%)1%
Net Margin1%2%(3%)1%
FCF Margin2%(0%)2%2%

Centene Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(2%)6%19%(2%)
Gross Profit Growth1258%(3%)(18%)1258%
EBITDA Growth56%10%(177%)(142%)
EBIT Growth385%(8%)(110%)(688%)
Net Profit Growth66%22%(302%)(126%)
FCF Growth(10%)(107%)(982%)(2%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Centene Operational KPIs

Centene's revenue per employee in the last FY averaged $3.2M, while opex per employee averaged $0.2M for the same period.

Centene's Rule of 40 is (1%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Centene's Rule of X is (4%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Centene
LTMLast FY202320242025202620272028
Rule of 40(0%)(1%)———
Bessemer Rule of X(2%)(4%)———
Revenue per Employee—$3.2M———
Opex per Employee—$0.2M———
G&A Expenses to Revenue7%7%——7%
Opex to Revenue—7%9%8%7%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Centene Competitors

Centene competitors include New China Life Insurance, Helvetia Baloise Holding, Aviva, Cincinnati Financial, WR Berkley, Sampo, QBE Insurance, Humana Inc., NN Group and Markel Group.

Most Centene public comparables operate across Insurance Carriers.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
New China Life Insurance1.1x1.1x3.3x3.8x
Helvetia Baloise Holding2.0x2.0x——
Aviva0.1x0.1x——
Cincinnati Financial1.9x2.4x——
WR Berkley1.7x2.0x8.6x8.5x
Sampo2.4x2.7x10.2x11.6x
QBE Insurance1.3x1.4x10.3x10.2x
Humana Inc.0.3x0.3x9.3x10.4x

This data is available for Pro users. Sign up to see all Centene competitors and their valuation data.

Start Free Trial

Centene M&A Activity

Centene has acquired 10 companies to date.

Last acquisition by Centene was on January 4th 2021. Centene acquired Magellan Health Services for $2B (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Centene

Magellan Health Services
PANTHERx Rare Pharmacy
Apixio
WellCare Health Plans
Description
Magellan Health Services is a Scottsdale-headquartered managed care organization overseeing behavioral health, substance use disorder treatment, and diagnostic imaging services for 40 million members. It administers pharmacy benefits and employee assistance programs through contracts with Medicaid plans in 30 states. Founded in 1969, the company partners with UnitedHealthcare and was acquired by Centene in 2022.
PANTHERx Rare Pharmacy is a specialty pharmacy dispensing therapies for rare diseases from its Pittsburgh, Pennsylvania headquarters. It serves patients with orphan drugs for conditions like spinal muscular atrophy and epidermolysis bullosa, offering home delivery, adherence support, and manufacturer reimbursement navigation.
Apixio is a San Mateo-headquartered healthcare technology company founded in 2009 that develops AI-driven platforms for risk adjustment, payment integrity, quality improvement, and care gap closure. Its Curvity platform processes clinical and claims data to generate patient health profiles and actionable insights for health plans and providers. Apixio supports transitions to value-based care by automating coding reviews and ensuring compliance with Medicare Advantage guidelines. The company partners with payers covering over 50 million lives across the United States and expanded into high-cost drug management solutions. In 2021, Centene Corporation acquired Apixio to enhance its analytics capabilities.
WellCare Health Plans is a managed care provider delivering Medicaid and Medicare Advantage services nationwide. Acquired by Centene Corporation in January 2020, it offers prescription drug plans, therapy services, caregiver training, and home modifications for seniors and families with complex needs. WellCare partners with local organizations to combat food insecurity and care barriers in served communities.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
Hartford, CT
Pittsburgh, PA
San Francisco, CA
Tampa, FL
Deal Date4 Jan 202115 Dec 20209 Nov 202027 Mar 2019
Valuation$2B$152Mundisclosed$17B
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Centene acquisitions and their M&A valuation multiples.

Start Free Trial

Centene Investment Activity

Centene has invested in 7 companies to date.

Latest investment by Centene was on October 8th 2023. Centene invested in Main Street Health in their $315M Undisclosed stage round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by Centene

Main Street Health
Hazel Health
Wayspring
Vida Health
Description
—
Hazel Health is a San Francisco-headquartered telehealth provider for K-12 schools across the United States. It connects students to board-certified clinicians via video for treating illnesses like flu, allergies, and mental health concerns. Hazel Health partners with over 300 districts in states including California and Texas, dispensing prescriptions through school dispensaries. Launched in 2019, it conducts 500,000 visits annually with 24/7 coverage.
Wayspring is a Boston-based value-based healthcare provider delivering medical, behavioral health, and social services to individuals with complex needs, particularly those with substance use disorders. The organization employs a longitudinal care model featuring member outreach, peer support networks, and provider collaborations to boost evidence-based treatment adherence and health outcomes while reducing costs. Wayspring serves members in multiple states through integrated primary care and recovery programs.
Vida Health is a San Francisco-headquartered virtual care platform founded in 2014 that integrates mental and physical health treatment via an AI-driven app. It delivers video sessions, messaging, and content for managing chronic conditions including obesity, diabetes, hypertension, stress, depression, and anxiety. Major U.S. employers and health plans such as HealthPartners partner with Vida to cover millions of lives.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
—
San Francisco, CA
Nashville, TN
San Francisco, CA
Deal Date8 Oct 202327 Oct 202228 Sep 20215 May 2021
RoundUndisclosed stageSeries CSeries DSeries D
Raised$315M$52M$75M$110M
InvestorsCentene; CVS Health; Echo Health Ventures; Elevance Health; Humana Inc.; LRVHealth; Oak HC/FT; UnitedHealthcareBain Capital Ventures; California HealthCare Foundation; Carrie Penner; Centene; Children's Memorial Health Institute; Firework Ventures; HLM Venture Partners; Hopelab; Memorial Hermann Hospital; Owl Ventures; Tao Capital Partners; UCSF Foundation Investment Company.406 Ventures; CareSource Foundation; Centene; Highmark Ventures; HLM Venture Partners; Oak HC/FT; The Blue Venture Fund; ValtruisAlly Bridge Group; AME Cloud Ventures; Ardea Partners; Aspect Ventures; AVP; Canvas Prime; Centene; General Atlantic; GuideWell; NGP Capital; Workday Ventures
Valuation$2B$353Mundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Centene investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Centene

When was Centene founded?Centene was founded in 1993.
Where is Centene headquartered?Centene is headquartered in United States.
How many employees does Centene have?As of today, Centene has over 61K employees.
Who is the CEO of Centene?Centene's CEO is Sarah M. London.
Is Centene publicly listed?Yes, Centene is a public company listed on NYSE.
What is the stock symbol of Centene?Centene trades under CNC ticker.
When did Centene go public?Centene went public in 2001.
Who are competitors of Centene?Centene main competitors include New China Life Insurance, Helvetia Baloise Holding, Aviva, Cincinnati Financial, WR Berkley, Sampo, QBE Insurance, Humana Inc., NN Group, Markel Group.
What is the current market cap of Centene?Centene's current market cap is $26B.
What is the current revenue of Centene?Centene's last 12 months revenue is $193B.
What is the current revenue growth of Centene?Centene revenue growth (NTM/LTM) is (1%).
What is the current EV/Revenue multiple of Centene?Current revenue multiple of Centene is 0.1x.
Is Centene profitable?Yes, Centene is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Centene?Centene's last 12 months EBITDA is $2B.
What is Centene's EBITDA margin?Centene's last 12 months EBITDA margin is 1%.
What is the current EV/EBITDA multiple of Centene?Current EBITDA multiple of Centene is 12.3x.
What is the current FCF of Centene?Centene's last 12 months FCF is $5B.
What is Centene's FCF margin?Centene's last 12 months FCF margin is 2%.
What is the current EV/FCF multiple of Centene?Current FCF multiple of Centene is 4.1x.
How many companies Centene has acquired to date?As of May 2026, Centene has acquired 10 companies.
What was the largest acquisition by Centene?$17B acquisition of WellCare Health Plans on 27th March 2019 was the largest M&A Centene has done to date.
What companies Centene acquired?Centene acquired WellCare Health Plans, Health Net, Fidelis Care, Magellan Health Services, PANTHERx Rare Pharmacy, Community Medical Group, Envolve Health, Apixio, MHM, and LifeShare Management Group.
In how many companies Centene has invested to date?As of May 2026, Centene has invested in 7 companies.
What was the last Centene investment?On 8th October 2023 Centene invested in Main Street Health, participating in a $315M Undisclosed stage round at $2B valuation, alongside CVS Health, Echo Health Ventures, Elevance Health, Humana Inc., LRVHealth, Oak HC/FT, and UnitedHealthcare.
In what companies Centene invested in?Centene invested in Main Street Health, Vida Health, Wayspring, Quartet Health, Hazel Health, Diameter Health, and RubiconMD.

See public comps similar to Centene

Lists including Centene

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial